Half Year 2025 Vimian Group AB Earnings Call Transcript
Key Points
- Vimian Group AB (VIMGF) reported a 15% total revenue growth in Q2, reaching EUR104.3 million.
- Specialty Pharma segment achieved all-time high revenues and adjusted EBITA for an individual quarter, with 6% organic growth.
- The Veterinary Services segment showed strong performance with 12% organic growth and a 60% increase in adjusted EBITA.
- The Diagnostics segment delivered an 18% organic growth, driven by the livestock diagnostics offering.
- The company completed the strategic acquisition of AllAccem to strengthen its dental offering, which is expected to contribute positively to the high-margin consumables in the dental portfolio.
- The Medtech segment underperformed, particularly in the Orthopedics business, leading to a 4% organic decline.
- The US Orthopedics market remains challenging, with customers working through existing inventories and applying tighter budgets.
- Adjusted EBITA growth was slower at 3% year-over-year, impacted by the weakness in Medtech Orthopedics.
- The company faced a 3% negative impact from currency movements in the quarter.
- Leadership changes, including the departure of the CEO and the head of the Medtech segment, indicate potential instability and a period of transition.
Welcome to the Vimian Group Q2 report 2025 presentation. (Operator Instructions)
Now, I will hand the conference over to the speakers CFO and Interim CEO, Carl-Johan Zetterberg Boudrie and Chairman of the Board, Magnus Welander. Please go ahead.
Thank you very much and good morning, everybody. It's not ordinary that a Chairman takes the start of the meeting, but as I'm sure you are aware, we had a press release last night where we announced that there has been a decision by the Board to make some changes to the leadership of the Vimian Group.
So Patrick Erickson, who has served for the last 1.5 year as CEO, is leading his role. And as you heard in the announcement, we have announced that Carl-Johan Zetterberg will take over as Interim CEO. So I wanted to introduce this and set the scene for before I hand over to Carl-Johan to go through the actual numbers of our performance in the second quarter.
What it comes down to is not anything wrong specifically or one thing
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
